1. Impact of VEGF Gene Polymorphisms in Elderly Cancer Patients: Clinical Outcome and Toxicity
   David Della-Morte et al, 2015, Pharmacogenomics CrossRef
2. Chemoprevention of Urothelial Cell Carcinoma Growth and Invasion by the Dual COX–LOX Inhibitor Licofelone in UPII-SV40T Transgenic Mice
   Venkateshwar Madka et al, 2014, Cancer Prevention Research CrossRef
3. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer
   E. Wieczorek et al, 2015, Clinical Biochemistry CrossRef
4. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
   Noah M. Hahn et al, 2017, Clinical Cancer Research CrossRef
5. Prognostic significance of Cyclin d1 / p16 / Ki-67 markers in bladder urothelial carcinomas
   İlyas Sayar, 2017, Ortadoğu Tıp Dergisi CrossRef
6. The effects of alternative splicing on miRNA binding sites in bladder cancer
   Seonggyun Han et al, 2018, PLOS ONE CrossRef
7. Targeted therapies in urothelial carcinoma
   Monalisa Ghosh et al, 2014, Current Opinion in Oncology CrossRef
8. Molecular Targets in Gynecologic Cancers
   Whitfield Growdon et al, 2014, Uncommon Gynecologic Cancers CrossRef
9. Loss of p53 and Acquisition of Angiogenic MicroRNA Profile Are Insufficient to Facilitate Progression of Bladder Urothelial Carcinoma in Situ to Invasive Carcinoma
   Francisco Ayala de la Peña et al, 2011, Journal of Biological Chemistry CrossRef
10. Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
    Noah M. Hahn et al, 2011, Journal of Clinical Oncology CrossRef
11. Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF as a Prognostic Factor in Patients with Hepatocellular Carcinoma
    Li Chen et al, 2011, The International Journal of Biological Markers CrossRef
12. Platelet-Derived Growth Factor Receptor Beta: A Novel Urinary Biomarker for Recurrence of Non-Muscle-Invasive Bladder Cancer
    Jiayu Feng et al, 2014, PLoS ONE CrossRef
13. The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism
    Emmanuelle Roche et al, 2014, Cellular Signalling CrossRef
14. Precision therapy in advanced urothelial cancer
    Joshua P. Schiff et al, 2019, Expert Review of Precision Medicine and Drug Development CrossRef
15. Angiogenesis in Gynecologic Cancers
    Whitfield Growdon et al, 2013, Tumor Angiogenesis Regulators CrossRef
16. The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development
    Paulina Wigner et al, 2021, International Journal of Molecular Sciences CrossRef
17. The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis
    Baoming Ren et al, 2014, World Journal of Surgical Oncology CrossRef
18. Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer
    Rehab S. Abdul-Maksoud et al, 2016, Gene CrossRef
19. Targeted therapies in the treatment of urothelial cancers
    Jeanny B. Aragon-Ching et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
20. Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
    Andrea B. Apolo et al, 2013, JNCI: Journal of the National Cancer Institute CrossRef
21. Alternative splicing ofVEGFA,APPandNUMBgenes in colorectal cancer
    Yi-Jun Zhao, 2015, World Journal of Gastroenterology CrossRef
22. VEGFA isoforms play a vital role in oral cancer progression
    Kinjal R. Patel et al, 2015, Tumor Biology CrossRef
23. Recommendations for the optimal management of early and advanced urothelial carcinoma
    Daniel Castellano et al, 2012, Cancer Treatment Reviews CrossRef
24. A Critical Review on Ramucirumab in the Treatment of Advanced Urothelial Cancer
    Panagiotis J Vlachostergios et al, 2018, Future Oncology CrossRef